AD4

HY-149428		
2918262-09	-4	
C ₅₅ H ₇₈ N ₄ O ₁₅		
1035.23		
PROTACs		
PROTAC		
Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month
	HY-149428 2918262-09 C ₅₅ H ₇₈ N ₄ O ₁₅ 1035.23 PROTACS PROTAC Powder In solvent	$\begin{array}{l} \text{HY-149428} \\ 2918262-09-4 \\ \text{C}_{55} \text{H}_{78} \text{N}_{4} \text{O}_{15} \\ 1035.23 \\ \text{PROTACS} \\ \text{PROTACS} \\ \text{PROTAC} \\ \text{Powder} \\ \text{POWder} \\ \text{C} \\ \text{A}^{\circ} \text{C} \\ \text{In solvent} \\ \text{C} \\ -80^{\circ} \text{C} \\ -20^{\circ} \text{C} \\ \end{array}$

MedChemExpress

SOLVENT & SOLUBILITY

	Solvent Mass Concentration	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	0.9660 mL	4.8298 mL	9.6597 mL
	5 mM	0.1932 mL	0.9660 mL	1.9319 mL
	10 mM	0.0966 mL	0.4830 mL	0.9660 mL

BIOLOGICAL ACTIVI	TY
BIOLOGICALACTIV	
Description	AD4 is an artemisinin derivative that is a proteolytic targeting chimera (PROTAC) targeting PCLAF. AD4 can effectively degrade PCLAF in RS4;11 cells (IC ₅₀ : 0.6 nM), thereby activating the p21/Rb axis and exerting anti-tumor activity. AD4 also prolonged survival of RS4;11-transplanted NOD/SCID mice, with in vivo efficacy ^[1] .
IC ₅₀ & Target	IC50: 0.6 nM (PCLAF/KIAA0101) ^[1]

CUSTOMER VALIDATION

• Glia. 2023 Oct 23.

See more customer validations on $\underline{www.MedChemExpress.com}$

Product Data Sheet

REFERENCES

[1]. Li Y, et al. Facilitated Drug Repurposing with Artemisinin-Derived PROTACs: Unveiling PCLAF as a Therapeutic Target. J Med Chem. 2023 Aug 24;66(16):11335-11350...

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA